Pharmaleads Clinical Advisory Board met on November 21 2017 in Paris to discuss the future clinical development of its two Dual ENKephalinase inhibitors (DENKIs).
The CAB comprises world-renowned pain specialists; Professor Nadine Attal and Dr. Didier Bouhassira from Ambroise Paré Hospital in Paris, Professor Andrew Rice from Imperial College in Lontodon and Dr. Dinesh Selvarajah from NHS Teaching Hospital in Sheffield.
After discussing Pharmaleads DENKIs clinical results, including the encouraging results of Phase 2a study with PL37 in painful diabetic neuropathy (PDN), the CAB strongly recommended the continued clinical development in neuropathic pain with Pharmaleads second DENKI PL265, due to its overall product profile being more suitable for the treatment of chronic pain.
The CAB also reaffirmed the decision to develop Pharmaleads original DENKI PL37 for the treatment of severe acute pain due to its extremely rapid onset of action.
